CY1111120T1 - Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση - Google Patents

Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση

Info

Publication number
CY1111120T1
CY1111120T1 CY20071100339T CY071100339T CY1111120T1 CY 1111120 T1 CY1111120 T1 CY 1111120T1 CY 20071100339 T CY20071100339 T CY 20071100339T CY 071100339 T CY071100339 T CY 071100339T CY 1111120 T1 CY1111120 T1 CY 1111120T1
Authority
CY
Cyprus
Prior art keywords
peptides derived
medical use
nerve fibers
protein nerve
protein
Prior art date
Application number
CY20071100339T
Other languages
English (en)
Inventor
Paul A Averback
Original Assignee
Nymox Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corporation filed Critical Nymox Corporation
Publication of CY1111120T1 publication Critical patent/CY1111120T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)

Abstract

Η παρούσα εφεύρεση απευθύνεται σε μεθόδους θεραπείας καταστάσεων που απαιτούν την απομάκρυνση ή την καταστροφή των βλαβερών ή ανεπιθύμητων κυττάρων σε έναν ασθενή, όπως καλοήθεις και κακοήθεις όγκοι, χρησιμοποιώντας πεπτίδια που παράγονται από τις αλληλουχίες αμινοξέων πρωτεϊνών των νευρικών ινών και σχετικών μορίων.
CY20071100339T 2001-05-25 2007-03-12 Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση CY1111120T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29315601P 2001-05-25 2001-05-25
EP02726037A EP1390403B1 (en) 2001-05-25 2002-05-24 Peptides derived from neural thread proteins and their medical use

Publications (1)

Publication Number Publication Date
CY1111120T1 true CY1111120T1 (el) 2015-06-11

Family

ID=23127882

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100339T CY1111120T1 (el) 2001-05-25 2007-03-12 Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση

Country Status (17)

Country Link
US (1) US6924266B2 (el)
EP (1) EP1390403B1 (el)
JP (1) JP4584573B2 (el)
KR (1) KR100945383B1 (el)
CN (1) CN1582301A (el)
AT (1) ATE350396T1 (el)
AU (1) AU2002256587B2 (el)
BR (1) BR0209990A (el)
CA (1) CA2448348C (el)
CY (1) CY1111120T1 (el)
DE (1) DE60217326T2 (el)
DK (1) DK1390403T3 (el)
ES (1) ES2278916T3 (el)
NO (1) NO334189B1 (el)
NZ (1) NZ529911A (el)
PT (1) PT1390403E (el)
WO (1) WO2002097030A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222745T2 (de) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
WO2003008443A2 (en) 2001-07-19 2003-01-30 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1847550A3 (en) * 2001-07-19 2008-01-09 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EA010687B1 (ru) * 2004-02-06 2008-10-30 Нимокс Корпорейшн Гуманизированное антитело
CN1909920A (zh) * 2004-03-18 2007-02-07 圣卢加医院 缓释剂的传送方法
CN101400364A (zh) * 2006-03-10 2009-04-01 尼莫克斯股份有限公司 用基于神经丝状蛋白的肽预防或降低癌症风险或发病率的方法
CN101215323B (zh) * 2007-12-28 2011-11-30 首都医科大学宣武医院 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
CN111579799A (zh) * 2020-06-23 2020-08-25 江苏省荣军医院 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145285T1 (de) * 1988-12-21 1996-11-15 Gen Hospital Corp Nachweis einer neurologischen krankheit oder einer funktionsstörung
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
KR20000075748A (ko) * 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
WO1999019347A1 (en) * 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
EP1089734A2 (en) * 1998-06-26 2001-04-11 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
WO2000018426A1 (fr) * 1998-09-30 2000-04-06 The Institute Of Physical And Chemical Research Inducteurs d'apoptose
WO2000034477A2 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
MXPA01006998A (es) * 1999-01-11 2002-05-06 Leadd Bv Uso de agentes inductores de apoptosis en el tratamiento de enfermedades (auto) inmunitarias.
CA2364209A1 (en) * 1999-03-26 2000-10-26 Human Genome Sciences, Inc. 49 human secreted proteins
EP1165827A4 (en) * 1999-03-26 2003-05-02 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
DE60222745T2 (de) 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
DK1392347T3 (da) 2001-05-16 2005-12-12 Nymox Corp Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner

Also Published As

Publication number Publication date
BR0209990A (pt) 2004-06-29
WO2002097030A2 (en) 2002-12-05
PT1390403E (pt) 2007-03-30
EP1390403B1 (en) 2007-01-03
DE60217326D1 (de) 2007-02-15
NO334189B1 (no) 2014-01-13
NO20035231D0 (no) 2003-11-25
ATE350396T1 (de) 2007-01-15
WO2002097030A3 (en) 2003-10-30
DE60217326T2 (de) 2007-10-18
NZ529911A (en) 2008-05-30
KR20040038913A (ko) 2004-05-08
CN1582301A (zh) 2005-02-16
US20030096350A1 (en) 2003-05-22
EP1390403A2 (en) 2004-02-25
NO20035231L (no) 2004-01-26
CA2448348A1 (en) 2002-12-05
JP2004534533A (ja) 2004-11-18
JP4584573B2 (ja) 2010-11-24
CA2448348C (en) 2013-07-16
DK1390403T3 (da) 2007-05-14
US6924266B2 (en) 2005-08-02
KR100945383B1 (ko) 2010-03-05
ES2278916T3 (es) 2007-08-16
AU2002256587B2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
CY1108009T1 (el) Αποτελεσματικα πεπτιδια στη θεραπεια ογκων ή αλλων ασθενειων που απαιτουν την εξαιρεση ή καταστροφη κυτταρων
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
EA199801044A1 (ru) Модуляторы регенерации тканей
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
DE69331813T4 (de) Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
EA200001124A1 (ru) Способ генной терапии
ATE536366T1 (de) Peptidinhibitoren von hk2 und deren anwendung
DE60018964D1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
EP1714979A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
SE9703287D0 (sv) Peptides
EP1847550A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells